Loading stock data…
ABSI
$6.83+0.28 (+4.27%)
After Hours$6.71-0.12 (-1.82%)· Last close Jun 9
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Absci Corporation in the Healthcare sector is trading at $6.83 with a market capitalization of $926M. Wall Street consensus targets $9.11 (10 analysts), implying a +33.4% move over the next 12 months. The stock is currently near its 52-week high of $7.39, remaining 92.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.83
Potential Downside
0%
Whystock Fair Value$6.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bow...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$926.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.87%
Volume
Today's trading volume
4.54M
Recent News
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036
A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself.
Absci Insider Buyers Pleased With US$700k Return On Investment
Insiders who bought Absci Corporation ( NASDAQ:ABSI ) in the last 12 months may probably not pay attention to the...
Marvell Stock Climbs After AMD Reveals Surprise Stake
AMD Reveals Marvell Stake, Sending Chip Stock Higher
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Absci (ABSI) Q1 2026 Earnings Call Transcript
Joining me today are Sean McClain, Absci Corporation's Founder and CEO; Zach Jonasson, Chief Financial Officer and Chief Business Officer; and Ronti Somerotne, Chief Medical Officer. Certain statements may also include projections regarding potential market opportunity.